<u>Title:</u> Circulating immunome fingerprint in eosinophilic esophagitis is associated with clinical response to proton pump inhibitor treatment

3

4 <u>Authors:</u>

Lola Ugalde-Triviño^{1,2*}, Francisca Molina-Jiménez^{1,2*}, Juan H-Vázquez^{3*}, Carlos
Relaño-Rupérez^{1,2,4}, Laura Arias-González^{2,6,7,8}, Sergio Casabona^{2,9}, María Teresa
Pérez-Fernández^{2,9}, Verónica Martín-Domínguez^{2,9}, Jennifer Fernández-Pacheco^{2,9},
Alfredo J Lucendo^{2,6,7,8}, David Bernardo^{3,5,&;#}, Cecilio Santander^{2,8,9,&,#}, Pedro
Majano^{1,2,8,10,&;#}

- 10
- 1. Molecular Biology Unit, Hospital Universitario de la Princesa, Madrid, Spain.
- Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS Princesa), Madrid, Spain.
- Mucosal Immunology Lab, Centro de Investigaciones Biomédicas en Red de
 Enfermedades Infecciosas (CIBERINFEC), Unidad de Excelencia Instituto de Biología
- 16 y Genética Molecular (IBGM), Universidad de Valladolid, 47005 Valladolid, Spain.
- 4. Bioinformatics Unit, Centro Nacional de Investigaciones Cardiovasculares (CNIC),
 Madrid, Spain
- 19 5. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas
 20 (CIBERINFEC), 28029 Madrid, Spain
- 6. Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, CiudadReal, Spain.
- 23 7. Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Spain.
- 24 8. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
- 25 (CIBERehd), Madrid, Spain.
- 9. Department of Gastroenterology, Hospital Universitario de La Princesa, Madrid,Spain.
- 10. Department of Cellular Biology, Faculty of Biology, Universidad Complutense deMadrid, Madrid, Spain.
- 30
- 31 * Co-first author
- 32 & Senior author
- 33 #Correspondence to:
- 34
- 35 Pedro L Majano, PhD
- 36 Hospital Universitario de la Princesa
- 37 Instituto Investigación Sanitaria Princesa (IP)
- 38 Diego de León 62
- 39 28006. MADRID. Spain
- 40 (pmajano@ucm.es / pedro.majano@salud.madrid.org)
- 41
- 42 Dr. Cecilio Santander, MD, PhD
- 43 Head of Department of Gastroenterology
- 44 Hospital Universitario de La Princesa
- 45 Instituto de Investigación Sanitaria Princesa IIS-IP
- 46 Madrid. Spain
- 47 (cecilio.santander@salud.madrid.org)

48

- 49 David Bernardo, PhD
- 50 Mucosal Immunology Lab, Universidad de Valladolid
- 51 Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM)
- 52 Centro de Investigaciones Biomédicas en Red de Enfermedades Infecciosas
- 53 (CIBERINFEC)
- 54 (d.bernardo.ordiz@gmail.com / <u>david.bernardo@uva.es</u>)

55

56

57 AUTHOR CONTRIBUTIONS

- 58 Conceived and designed the study: AJL, DB, CS, PM.
- 59 Participated in the clinical management of patients: SC, MTF-P, VM-D, JF-P, CS.
- 60 Performed the experiments: LU-T, FM-J, JH-V, LA-G, PM.
- Analysed and discussed the data: LU-T, FM-J, JH-V, CR-R, DB, PM.
- 62 Wrote the paper: LU-T, DB, JH-V, CS, PM.
- 63 All the authors read, provided comments, and approved the final version of the
- 64 manuscript.
- 65

66 AUTHOR DISCLOSURE

67 None to declare

68

69 ORCID NUMBERS

- 70 Lola Ugalde-Triviño: 0000-0002-0911-8043
- 71 Francisca Molina-Jiménez: 0000-0003-4912-1025
- 72 Juan H-Vázquez: 0000-0002-4805-2403
- 73 Carlos Relaño-Rupérez: 0000-0002-1407-9245
- 74 Laura Arias-González: 0000-0003-2132-9350
- 75 Sergio Casabona: 0000-0002-6131-8341
- 76 María Teresa Pérez-Fernández: 0000-0003-0363-2516
- 77 Verónica Martín-Domínguez: 0000-0001-6839-2707
- 78 Jennifer Fernández-Pacheco 0000-0002-5384-0658
- 79 Alfredo J Lucendo: 0000-0003-1183-1072
- 80 David Bernardo: 0000-0002-2843-6696
- 81 Cecilio Santander: 0000-0001-5492-2535
- 82 Pedro Majano: 0000-0002-5495-1413
- 83

84

- 85
- _ _
- 86
- 87
- 88
- 89
- 90

91 WHAT IS KNOWN

- Eosinophilic esophagitis (EoE) is a Th2 type immune disorder with increased
 prevalence in the last years.
- Proton pump inhibitor (PPI) treatment is the preferred first-line therapy for
 EoE, which leads to clinical and pathological reversion in about half of the
 cases. Non-responding patients require other therapeutic options.
- 97 Currently, an endoscopy with esophageal biopsies is required for EoE
 98 diagnosis and to monitor response to treatment. Therefore, the discovery of
 99 non-invasive biomarkers is of utmost importance for treatment monitoring.

To date only peripheral eosinophil and Th2 profiles have been studied in EoE.

- 100
- 101

•

102 WHAT IS NEW HERE

- At diagnosis EoE patients have a specific circulating immune signature.
- PPI-responding and non-responding EoE patients have different immune
 fingerprints at baseline.
- Immune characterization of EoE patients at diagnosis and after PPI treatment unveiled differential levels of circulating plasmacytoid dendritic cells (pDCs) depending on their inflammatory state and response to PPI treatment. Those levels are related with the number of pDCs infiltrated in the esophageal tissue.
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126

127 ABSTRACT

128 **Objectives:** The aim of the study was to characterize the circulating immunome of 129 patients with EoE before and after proton pump inhibitor (PPI) treatment in order to 130 identify potential non-invasive biomarkers of treatment response.

Methods: PBMCs from 19 healthy controls and 24 EoE patients were studied using a 39-plex spectral cytometry panel. The plasmacytoid dendritic cell (pDC) population was differentially characterized by spectral cytometry analysis of immunofluorescence assays in esophageal biopsies from 7 healthy controls and 13 EoE patients.

Results: Interestingly, EoE patients at baseline had lower levels of circulating pDC 135 136 compared with controls. Before treatment, patients with EoE who responded to PPI 137 therapy had higher levels of circulating pDC and classical monocytes, compared with non-responders. Moreover, following PPI therapy pDC levels were increased in all EoE 138 139 patients, while normal levels were only restored in PPI-responding patients. Finally, 140 circulating pDC levels inversely correlated with peak eosinophil count and pDC count in 141 esophageal biopsies. The number of tissue pDCs significantly increased during active EoE, being even higher in non-responder patients when compared to responder 142 143 patients pre-PPI. pDC levels decreased after PPI intake, being further restored almost 144 to control levels in responder patients post-PPI.

Conclusions: We hereby describe a unique immune fingerprint of EoE patients at
 diagnosis. Moreover, circulating pDC may be also used as a novel non-invasive
 biomarker to predict subsequent response to PPI treatment.

148

149 KEY WORDS

150 Spectral cytometry, Biomarker, Eosinophilic esophagitis, Plasmacytoid dendritic cells

151

152 ABBREVIATIONS

153

- 154 EoE: Eosinophilic esophagitis
- 155 EoEHSS: Eosinophilic Esophagitis Histologic Scoring System
- 156 EREFS: EoE endoscopic reference score
- 157 GERD: Gastro-esophageal reflux disease.
- 158 LN: Lymph node
- 159 LogFC: Log2 Fold Change
- 160 NR: Non-responder
- 161 PBMCs: Peripheral blood mononuclear cells
- 162 pDC: Plasmacytoid dendritic cells
- 163 PPI: Proton Pump Inhibitors
- 164 R: Responder
- 165 Th2: T helper 2 cells
- 166 UMAP: Uniform Manifold Approximation and Projection
- 167
- 168
- 169
- 170
- 171

172 FINANCIAL SUPPORT

PM and CS are supported by grants PI17/0008 and ISCIII-Proteored 2019 of Instituto de Salud Carlos III (ISCIII, Spain) and co-funded by Fondo Europeo de Desarrollo Regional (FEDER). CS is also funded by Asociación Española de Gastroenterología (AEG) 2019 grant. DB is funded through the Spanish Ministry of Science [PID2019-104218RB-I00], Programa Estratégico Instituto de Biología y Genética Molecular (IBGM Junta de Castilla y León. Ref. CCVC8485) and the European Commission -NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform. LU-T is recipient of an INVESTIGO contract from Comunidad de Madrid (09-PIN1-00015.6/2022) partly funded by the European Social Fund, NextGenerationEU, and Recovery, Transformation and Resilience Plan. CR-R is recipient of an INVESTIGO contract from Ministry of Labour and Social Economy, the national public employment service (SEPE) (INVESTIGO Exp. 2022-C23.I01.P03. S0020-0000031) partly funded by the European Social Fund, NextGenerationEU, and Recovery, Transformation and Resilience Plan.

188 ACKNOWLEDGMENTS

We acknowledge, Instituto de Salud Carlos III, FEDER organization, Spanish Gastroenterology Association and Spanish Ministry of Science for the support to this study. Also, we would like to acknowledge the support from European Social Fund, NextGenerationEU, and Recovery, Transformation and Resilience Plan. We express our gratitude to Dr. Manuel Gómez for critical review of the manuscript and English editing.

197198 Word count: 3856

220 221

222 INTRODUCTION

223

Eosinophilic esophagitis (EoE) is a Th2-type immune disorder which is considered an increasing leading cause of chronic esophageal dysfunction in patients of all ages^{1,2} just after gastro-esophageal reflux disease (GERD).

227 Eosinophils are normally found in the gastrointestinal tract; however, they are absent from the esophageal tissue in health conditions. In EoE, the eosinophil infiltrate in the 228 esophageal tissue layers^{3,4} leads to tissue remodelling and fibrosis as well as 229 subsequent dysfunction characterized by esophageal dysmotility, narrowing and 230 231 rigidity⁵. As a result, patients experience food impaction, dysphagia and heartburn 232 among other symptoms, which impair their health-related quality of life. Therefore, an 233 early EoE diagnosis and effective therapy are essential to prevent impairment of 234 esophageal function. EoE patients often have concurrent allergic responses to food and airborne allergens, together with a yet unexplained male predominance^{6,7}. 235

First-line therapeutic options for EoE include dietary restrictions, protein pump inhibitor 236 237 (PPI) therapy and swallowed topical corticosteroids, which provide variable 238 effectiveness^{8–12}. Recently, the anti-interleukin-4 receptor antagonist dupilumab joined the therapeutic armamentarium against EoE^{13,14}. Among them, PPI represent the 239 preferred therapy in clinical practice, despite its limited effectiveness¹⁵; histologic 240 241 remission and clinical improvement after PPI are achieved by only 50% and 70% of treated patients, respectively¹⁶. Patients who do not respond to PPI require 242 243 subsequent therapeutic options.

244 Currently, EoE diagnosis and treatment response monitoring require endoscopy with 245 esophageal biopsies, as clinical symptoms do not correlate well with esophageal inflammation^{17,18}. In this regard, the chronic nature of this disease together with the 246 dissociation between patients' symptoms and esophageal inflammation¹⁸ require 247 seeking for novel reliable biomarkers and clinical parameters able to identify patient 248 profiles at diagnosis and follow-up. Recent studies have focused on seeking for new 249 biomarkers by characterizing the RNA¹⁹⁻²¹ and proteomic profile of EoE at esophageal 250 tissue level²². Nevertheless, these approaches are still invasive. Hence, the 251 252 development of novel non-invasive biomarkers to aid on EoE diagnosis and monitoring 253 is an essential unmet need²³.

Building from all these precedents, in this study we aimed to characterize the circulating immunome of EoE patients at the time of diagnosis using top-of-the-art spectral cytometry. With this approach, we expected to identify specific immune subsets that could not only help to characterize this disorder, but also to identify novel non-invasive biomarkers able to predict response to PPI treatment.

259 260

261 MATERIAL AND METHODS

262

263 Human subjects

264

A total of 25 incident adult EoE patients were prospectively recruited at the moment of diagnosis at Hospital Universitario de La Princesa (Madrid, Spain) between February 2018 and November 2020. EoE was diagnosed according to evidence-based

auidelines³ including: (i) symptoms referring to esophageal dysfunction. (ii) infiltration of 268 the esophageal epithelium by 15 or more eosinophils per high-powered field (hpf) 269 270 assessed from 6 endoscopic biopsy samples; (ii) absence of eosinophilic infiltration in 271 biopsy specimens from gastric and duodenal mucosa; and (iii) exclusion of alternative 272 potential causes of esophageal eosinophilia. Subjects (n=19) who underwent upper endoscopy for assessment of dyspepsia or suspected gastroduodenal ulcer were 273 274 included as controls. Esophageal biopsies obtained in the endoscopy were normal in 275 all cases and eosinophilic infiltration was excluded. All controls with hiatus hernia, 276 incompetent cardias, or esophageal peptic lesions were excluded hence ensuring that all the recruited controls displayed a normal endoscopic appearance and eosinophil-277 278 free biopsies of the esophagus.

- Atopic background was recorded for all EoE patients and control subjects. The EoE endoscopic reference score (EREFS) rating the severity of esophageal inflammation (oedema, furrows, exudates) and fibrosis (rings and stricture)²⁴ was assessed in all patients. Furthermore, the validated Eosinophilic Esophagitis Histologic Scoring System (EoEHSS) was also determined, evaluating eight pathologic features for both severity (grade) and extent (stage) of abnormalities²⁵.
- Out of the 25 EoE patients, 18 underwent double dose PPI treatment (omeprazole 20 mg b.i.d. or equivalent) for an 8-week period, after which they were classified as responders (n=9) or non-responders (n=9) based on the peak eosinophil count in a second endoscopy in which EREF and EoEHSS scores were also assessed. The study was approved by the local Ethics Committee (PI17/0008, registry number 3107, 8 June 2017). All individuals provided written informed consent.
- 291

292 Blood samples

In all cases, blood samples were obtained at the time of the endoscopy from EoE patients (both before and after PPI-treatment in the latter) and controls. After placing a venous line to provide sedation for endoscopy, blood was collected in EDTA-coated tubes to isolate peripheral blood mononuclear cells (PBMC).

297

298 **PBMCs staining and spectral cytometry acquisition**

PBMCs were isolated by Ficoll gradient assay. Viable cells were counted and
 cryopreserved in freezing medium (Foetal bovine serum [Hyclone,Thermofisher]
 complemented with DMSO 20% medium) at vapour phase of liquid nitrogen.

302 For the analysis, PBMCs were thawed and a total of 2 million PBMCs were stained with monoclonal antibodies (Supplementary Table 1) applying a modified OMIP-69 panel 303 protocol²⁶. Before staining, Live/Dead fixable blue dead cell stain kit was added to 304 exclude dead cells from the analysis. Brilliant Stain Buffer and True-Stain Monocyte 305 306 Blocker were also added before staining with the aim of obtaining the optimal 307 fluorescence. PBMCs were washed with FACS buffer (500mL PBS +1 0mL filtered 308 FCS + 0.1g NaN₃ + 2.5mL sterile EDTA) and incubated in the dark at room 309 temperature during staining. Cells were further fixed in 0.8% paraformaldehyde in FACS buffer in the dark for 10min and washed with FACs buffer. Cells were preserved 310 311 at 4°C until acquired (within 48h) in a 5-laser spectral cytometer (Aurora, Cytek).

312

313 Cytometry data and statistical analysis

Spectral cytometry data were analysed using the OMIQ Data Science platform (© Omiq, Inc. 2022). After setting the scale, parameters, and cofactors, the FlowAI

algorithm was used for cleaning the data from aberrant signal patterns or events. Then, 316 317 cell debris and doublets were excluded to gate viable leukocytes (CD45⁺) where an unsupervised approach was applied with a dimensionality reduction Uniform Manifold 318 Approximation and Projection (UMAP)²⁷ plus clustering FlowSOM algorithms. Merging 319 320 these two algorithms allows a deeper classification of the different immune subsets through different marker expression on the UMAP. A heatmap was also built showing 321 the expression levels of each marker within each cluster. Dendrograms further grouped 322 the clusters and markers associated by similarity. 323

324 Statistical analysis was performed in all cases using Rstudio 2022.07.2+576. Differential analysis of clusters defined in OMIQ was performed with the edgeR 325 326 package, using genewise quasi-likelihood (QL) F-tests with GLMs. Significance was set at p-value≤ 0.05 and Log2 Fold Change (LogFC) ≥1.5. Differences between groups of 327 328 significant clusters were validated by classic gating strategy approaches 329 (Supplementary Figure 1 and 2). Manual gating results were analysed by t-test (paired 330 when indicated) and/or two-way ANOVA test followed by post hoc Fisher test. Outliers 331 were determined through Grubbs' test and deleted from the final analysis. Statistical significance was considered when p-value ≤0.05 in all cases (p< 0.05 *, p< 0.01 **, 332 p<0.001 ***, p<0.0001****, n.s.= not significant). Percent of total always refers to 333 334 percentage of cells of the specified population relative to total PBMCs.

335

336 Immunofluorescence staining in esophageal biopsies

337

338 Immunofluorescence staining was performed in biopsies from control subjects and EoE patients, previously oriented in a cellulose acetate and included in paraffin-embedded 339 340 blocks, using the antibodies CD123-biotin (Stem Cell, 60110BT), HLA-DR (Santa Cruz, sc-53319) and CD11c (Thermo Fisher Scientific, PA535326). Briefly, slides with 4-µm 341 342 sections of esophageal biopsies, underwent deparaffinization, antigen retrieval using 343 sodium citrate buffer (pH 6.0), blocked with 4% goat serum/phosphate-buffered saline 344 (PBS), and then incubated with primary antibody (HLA-DR and CD11c) diluted in 1% goat serum-PBS overnight at 4 °C in a humidified chamber. Then, slides were washed 345 346 with PBS + 1% NP-40 and incubated with secondary antibodies diluted in 1% goat serum-PBS for 30min at RT in a humidified chamber. After, slides were washed with 347 PBS + 1% NP-40 and incubated with primary antibody (CD123) diluted in 1% goat 348 349 serum/PBS overnight at 4 °C in a humidified chamber. Finally, slides were washed in 350 PBS + 1% NP-40 and incubated with secondary antibodies and DAPI (0.5 µg/mL) diluted in 1% goat serum/PBS for 30min at RT in a humidified chamber. Finally, a cover 351 352 slip was added with ProLong Gold mounting reagent (Molecular Probes). Images were 353 obtained using a Thunder Imager (Leica) with LAS X software and analysis was done 354 using ImageJ and RStudio software. Normality was assessed by Saphiro Wilk normality test, the non-parametric Mann-Whitney test was done to compare between 355 pairs of groups. In all cases (p< 0.05 *, p< 0.01 ***, p<0.001 ***, p<0.0001 ****, n.s.= not 356 357 significant).

358

359 RESULTS

360

361 Patient Demographics

Clinical and demographic characteristics of study participants are summarized in Table 1. Compared to controls (n=19), EoE patients (n=25) were older (34 vs 41 years) and more frequently male (68% vs 88%), but no significant differences were found in demographic characteristics across groups.

EoE patients treated with PPI (n=18) were classified as responders or non-responders to the therapy. EoE remission was defined as presenting a peak eosinophil count below 15 after at least 8 weeks of treatment. Response to PPI was also associated with improvement in EoE symptoms from baseline (assessed as patient reported outcomes), as well as in endoscopic and histologic characteristics, assessed with the scores EREFS and Grade and Stage EoEHSS, respectively. Baseline characteristics of PPI responding, and non-responding patients showed no differences.

	Control (n=19)	EoE (n=25)	p-value	Responders (n=9)	Non-Responders (n=9)	p-value
Sex (male) (n,%)	13 (68%)	20 (80%)	0.488	7 (77%)	7 (77%)	1
Age (mean years ± s.d.)	34.42 ± 10.93	41 ± 13.7	0.060	33 ± 12.85	44 ± 14.95	0.152
Symptoms (n,%)						
Dysphagia	0	23 (92%)	<0.001	9 (100%)	9 (100%)	1
Food impaction	0	16 (64%)	< 0.001	7 (77%)	5 (55%)	0.619
Heartburn	o	10 (40%)	0.002	3 (33%)	3 (33%)	1
Abdominal pain	0	0 (0%)	1	0 (0%)	0 (0%)	1
Any atopic disease (n,%)						
Atopic diseases	1 (5%)	20 (87%)	<0.001	8 (88%)	9 (100%)	1
Asthma	o	5 (22%)	0.053	3 (33%)	1 (11%)	0.57
Allergic rhinitis/sinusitis	1 (5%)	19 (82%)	<0.001	8 (88%)	9 (100%)	1
Food allergy	2 (10%)	11 (48%)	0.0173	5 (55%)	3 (33%)	0.63
Endoscopic findings (n,%)						
EREFS (mean ± s.d.)	0	3.36 ± 2	<0.001	2.44 ± 2.06	3.88 ± 1.26	0.09
EREFS PostPPI (mean ± s.d.)			-	1.44± 1.51	4.33± 1	<0.00
Maximum eosinophil count (mean ± s.d.)	0	55.68 ± 23.9	<0.001	46.22 ± 21.76	65.56 ± 19.43	0.06
Maximum eosinophil count PostPPI (mean ± s.d.)	-	•	-	1.44 ± 2	65 ± 20.91	<0.00
Histological findings						
EoEHSS Grade (0-1) (mean ± s.d.)	0	0.50 ± 0.19	<0.001	0.43 ± 0.22	0.57 ± 0.15	0.12
EoEHSS Grade (0-1) PostPPI (mean ± s.d.)	-			0.06 ± 0.04	0.40 ± 0.22	0.00
EoEHSS Stage (0-1) (mean ± s.d.)	0	0.47 ± 0.16	<0.001	0.43 ± 0.17	0.57 ± 0.15	0.12
EoEHSS Stage (0-1) PostPPI (mean ± s.d.)	-		-	0.02 ± 0.03	0.31 ± 0.19	0.00
PPI Treatment				6 (66%)	2 (22%)	0.138
Omeoprazol				2 (22%)	2 (22%)	
Esomeprazol				1 (11%)	5 (55%)	
Pantoprazol					0 (00 /0)	

373

Table 1. Clinical features of controls and EoE patients. Fisher's test and *t*-test were
 applied to analyse differences between control and EoE patients and between
 responders and non-responders. P-value is shown for each comparison. Abbreviations:
 EoE: Eosinophilic Esophagitis; EoEHSS: Eosinophilic Esophagitis Histologic Scoring
 System; EREFS: EoE endoscopic reference score; PPI: Proton Pump Inhibitors.

379 High dimensional analysis on PBMCs from controls and EoE patients

A total of 61 samples (19 controls, 24 patients at disease onset, as well as 9 380 responders and 9 non-responders to PPI after 8-week treatment) were analysed by 381 382 UMAP identifying four major continents and several smaller islands (Figure 1A). The 383 relative expression of each marker on the UMAP (Supplementary Figure 3) revealed that the main continent on the left represents cytotoxic (CD8⁺) T-cells together with 384 double negative (CD4 CD8) T-cells. On the other hand, the main continent on the right 385 is composed of helper (CD4⁺) T-cells. Likewise, the island on the bottom is mainly 386 387 composed of monocytes, basophils and myeloid antigen presenting cells (APC), while the islands in the middle represent NK cells and $\Box \delta$ T-cells. B-cells are represented in 388 389 the top island together with dendritic cells.

390

To further refine the analysis, FlowSOM algorithm was applied to find similar cell subsets and separate them into metaclusters in an unsupervised manner (Figure 1B).

393 The overlay of the FlowsSOM clustering on the UMAP representation (Figure1C) 394 allowed us to perform a more exhaustive analysis, identifying a total of 73 clusters according to surface marker expression as shown in the heatmap (Figure 1D). 395 Supplementary Table 2 shows an in-depth characterization of the phenotype of all 396 clusters, which allowed the identification of 70 of them, since clusters 13, 32 and 33 397 398 could not be clearly identified. Finally, all clusters were further uploaded into the UMAP (Figure 1E) to determine not only how they relate to each other, but also to display their 399 pseudoevolution. 400






Figure 1. High dimensional analysis of peripheral blood mononuclear cells from
 controls and EoE patients.

(A) UMAP density analysis representation performed on singlets corresponding to total
 viable circulating CD45⁺ cells from all samples. Samples were obtained from 19
 controls and 24 patients at disease onset, as well as 9 responders and 9 non-

407 responders to PPI therapy after 8-week treatment (a total of 61 samples). (B) FlowSOM clustering on total viable singlet CD45⁺ cells identified the main metaclusters 408 on dataset: B-cells, NK cells, γδ T-cells, CD4⁺ T-cells, CD8⁺ T-cells, dendritic cells, 409 410 basophils, monocytes, CD4 CD8 T-cells, and NKT-like cells. (C) UMAP representation of all samples after non-supervised FlowSOM clusterization (D) Heatmap displaying 411 the relative expression of each marker within each of the 73 identified clusters. 412 Euclidean distance between clusters was calculated and represented by the 413 dendrogram at the left side of the plot. (E) All 73 identified clusters were overlaid on the 414 UMAP projection. Each identified cluster is tagged by a specific colour and number as 415 416 shown in the legend.

417 418

419 Peripheral immune profile differs between EoE patients and controls at baseline 420 visit

421 After characterizing the different clusters, or immune subsets, present in our samples, we next addressed the immune differences found between controls and EoE patients 422 at baseline visit. Volcano plot representation (Figure 2A) showed a significant deficit of 423 plasmacytoid dendritic cells (pDC) (C-26) in EoE patients and an expansion of CD4⁻ 424 CD8⁻ and early effector CD8⁺ T-cells (Clusters 37 and 69) at the time of disease 425 diagnosis (Figure 2B). In order to further confirm these findings, classical gating 426 427 strategies were applied as shown in Supplementary Figure 2, hence confirming that 428 EoE patients display a deficit of circulating pDC at disease onset (Figure 2C).

429




Figure 2. Peripheral immune profile differs between EoE patients and controls at

432 baseline visit.

430

(A) Volcano plot analysis comparing clusters from controls (n=19) and patients with 433 434 eosinophilic esophagitis at disease diagnosis (EoE, n=24). LogFC and -Log(p-value) are shown. Clusters considered statistically significant are shown in red together with 435 436 their nature as elucidated from Supplementary Table 2. (B) These differentially 437 expressed clusters between control and EoE patients are further shown in the UMAP representation. (C) Validation of these clusters was performed following classical 438 439 gating approaches (Supplementary Figure 1 and 2). t-test was applied in panel D, considering a p-value <0.05 as statistically significant (*p<0.05). Percent of total always 440 refers to percentage of cells of the specified population relative to total PBMCs. 441


442

443 Circulating pDC and classical monocyte levels at baseline are associated to PPI 444 response.

445

After describing that 3 clusters were differentially expressed on EoE patients at disease
 diagnosis, with a specific reduction of circulating pDCs as confirmed by classical gating
 approaches, we next aimed to address whether we could also identify specific clusters
 that might predict patient's response to PPI treatment.

To that end, we compared the immune profile of responding (R) and non-responding 450 (NR) patients (Table1) at disease onset (i.e., before PPI treatment [PrePPI]) (Figure 451 452 3A). Our results revealed that responding patients at diagnosis had higher levels of circulating pDC, myeloid antigen presenting cells and classical monocytes; together 453 with lower levels of mature NK cells, and no memory B-cells and central memory CD4⁺ 454 T-cells (Figures 3B and 3C). Of note, further analysis following classical gating 455 approaches confirmed that PPI-responding patients had higher levels of circulating 456 457 pDC and classical monocytes at disease onset compared to non-responders (Figure 458 3D).



459

Figure 3. Circulating pDC and classical monocyte levels are associated to PPI response at disease diagnosis

(A) Volcano plot of differential analysis between responding (R, n=9) and non-462 463 responding patients (NR, n=9). LogFC and -Log(p-value) at baseline are shown. Clusters considered statistically significant are highlighted in red, showing their name 464 465 and number. (B) UMAP representation from R and NR patients, in which significant clusters are coloured. (C) Validation by classic gating (Supplementary Figure 1 and 2) 466 467 of the significant clusters previously defined. Boxplots of significant clusters represent 468 individual percentage of total value, group medians as well as minimum and maximum values. Differences were analysed by t-test considering p-values <0.05 as statistically 469 significant (*p<0.05, **p< 0.01, ***p< 0.001, ****p<0.0001) (R n=8, NR n=7). Responder 470 (R), Non-Responder (NR), before treatment (PrePPI). Percent of total always refers to 471 472 percentage of cells of the specified population relative to total PBMCs.

473

474 Circulating pDC levels are restored in PPI-responding patients following 475 treatment

476


477 Since patients with PPI responsive and non-responsive EoE displayed different 478 immune cell levels at the time of disease diagnosis, we next aimed to address whether 479 we could also identify specific clusters modulated by PPI treatment. To that end, we

next compared the profile of EoE responsive (R) patients both before (PrePPI) and
after (PostPPI) PPI therapy (Table1).

482 Our results revealed that, following treatment, circulating levels of pDC (C-26) and 483 basophils (C-14) were increased in PPI-responding patients (Figures 4A and 4B), 484 something particularly relevant in the case of circulating pDC as that increase was 485 further confirmed by classical gating approaches (Figure 4C).

Based on these observations, we also assessed the immune cell dynamics in nonresponding patients (Supplementary Figure 4A). The pDC cluster was increased in these patients following treatment (Supplementary Figure 4B); however, that observation could not be confirmed following classical gating strategy (Supplementary Figure 4C). Therefore, taken all together our results suggest that clinical response to PPI-treatment is associated with an increase in circulating pDC levels.

492



493 494

Figure 4. pDC and basophil levels are increased in responding patients upon PPI treatment.


497 (A) Volcano plot analysis of the clusters comparing patients responding to proton pump inhibitor (PPI) treatment, both before (R-PrePPI) and after (R-PostPPI) therapy. LogFC 498 499 and -Log(p-value) are shown. Clusters considered statistically significant are shown in red together with their nature as elucidated from Supplementary Table 2. (B) UMAP 500 representation of these differentially expressed clusters in R-PrePPI and R-PostPPI. 501 502 (C) Further validation of these clusters was performed following classical gating approaches as shown in Supplementary Figure 1 and 2. Boxplots of significant clusters 503 504 represent individual percentage of total value, group medians as well as minimum and 505 maximum values. Red line indicates paired PrePPI and PostPPI samples. Differences were analysed by paired *t*-test considering p-values <0.05 as statistically significant
(*p<0.05, **p< 0.01, ***p< 0.001, ****p<0.0001) (n=8). Responder (R), before PPI
treatment (PrePPI), after PPI treatment (PostPPI). Percent of total always refers to
percentage of cells of the specified population relative to total PBMCs.

510

511 Circulating pDCs are associated with EoE pathology and PPI-response

Having described that pDCs are differentially decreased in EoE patients at the moment 512 of diagnosis, (Figure 2) while within EoE patients they are higher in those who respond 513 to PPI treatment (Figure 3) and, indeed, they are further increased following such 514 clinical intervention (Figure 4) although not in non-responding patients (Supplementary 515 516 Figure 4), we next decided to focus on this cell population. Hence, further analysis confirmed that all EoE patients had lower levels of circulating pDCs at diagnosis, 517 although these levels were lower in non-responding patients than in responders. 518 519 Furthermore, in responders pDC levels were indeed further restored to control levels 520 following treatment.

521 Since pDCs seem to be related to disease remission, we next hypothesized that cells 522 might be correlated with the esophageal inflammatory state of the patient. To test this 523 hypothesis, we studied the correlation between the maximum eosinophil count in the 524 esophageal biopsy and pDC levels (Figure 5B). We found a negative correlation (r =-525 0.44 p-value= <0.001), suggesting the implication of pDCs in EoE pathogenesis. 526





528 Figure 5. Circulating pDC are associated with EoE pathology and PPI-response

(A) Boxplots represent levels of pDC in control and EoE patients before and after PPI treatment, as individual percentages of total counts as well as group medians and minimum and maximum values. Differences were analysed by *t*-test, considering p-values <0.05 as statistically significant. (B) Pearson correlation between pDC and peak eosinophil count. Pearson correlation coefficient and p-value are shown. (Control n=19, R n=9, NR n=9). Responder (R), Non-Responder (NR), before PPI treatment (PrePPI), after PPI treatment (PostPPI) (*p<0.05, **p< 0.01, ***p< 0.001, ****p<0.0001).

- 536
- 537
- 538
- 539
- 540
- 541

542

543 Differential activation profile of circulating pDCs in EoE and remission

544

Next, we assessed the expression of the chemokine receptors CCR7 and CXCR3 on circulating pDC, as they mediate pDC migration towards the lymph nodes (LN) and peripheral sites of inflammation^{28,29} (Figure 6A). CXCR3⁺ pDC (either CCR7⁺ or CCR7⁻) were increased in PPI responding patients following treatment (Figure 6B) suggesting a potential mechanism of action for pDC related with their infiltration in the esophagus.

551

552 553






Figure 6. Differential activation profile of circulating pDC in EoE and remission. (A) Gating of activated pDC subpopulations according to their CCR7 and CXCR3

expression: CCR7⁻/CXCR3⁺(blue), CCR7⁺/CXCR3⁺ (orange), CCR7⁺/CXCR3⁻ (green), 556 CCR7/CXCR3⁻ (red). Dot plots show representative distribution of these 557 subpopulations in each cohort. (B) Boxplot representation of the different pDC 558 559 activation profiles in the five cohorts . Total count, group median and minimum and 560 maximum values are represented. Differences were analysed by multiple comparison ANOVA followed by post hoc Fisher's test, considering p-values <0.05 as statistically 561 significant (*p<0.05, **p< 0.01, ***p< 0.001, ****p<0.0001). (Control n=19, R n=9, NR 562 n=9). Responder (R), Non-Responder (NR), before treatment (PrePPI), after treatment 563 (PostPPI). 564


565

566 pDC infiltration in esophageal biopsies of EoE patients

567

Finally, after describing the activation profile of the circulating pDC population, we 568 studied by immunofluorescence assay the infiltration of these cells in esophageal 569 biopsies of 7 healthy controls and 13 EoE patients (6 R and 7 NR) before and after PPI 570 treatment (Figure 7). pDCs were characterized as CD123⁺ (red) HLA-DR⁺ (green) 571 CD11c⁻ (blue) cells and quantified per mm² of tissue (Figure 7A). The number of tissue 572 pDCs was significantly higher in EoE patients than in controls (Figure 7B), being higher 573 in NR-prePPI when compared to R-prePPI (Figure 7C). The number of tissue pDCs 574 was reduced in NR and R patients after PPI treatment although differences were not 575 576 statistically significant. However, R-postPPI values were the closest to those of 577 controls (Figure 7C).

578 In general, tissue pDCs inversely correlated with the circulating pDC count and were 579 directly related with the number of eosinophils per mm² (Figure 7D,E). Thus, levels of 580 this immune population seem to be related with PPI-response and EoE activity.



581

Figure 7. pDC infiltration in esophageal biopsies of EoE patients (A) 582 583 Immunofluorescence analysis of pDC infiltrate in esophageal biopsies from EoE patients. pDCs were visualized as CD123⁺(red) CD11c⁻ (blue), HLA-DR⁺ (green) cells. 584 Arrows point to representative examples of pDC. Scale bar is shown. Nuclei were 585 stained with DAPI (represented in grey in merged images). (B) Boxplot representation 586 of infiltrating pDCs in controls (n=7) and EoE (n=13) patients at baseline. Relative 587 count per mm², group median and minimum and maximum values are represented. 588 Differences were analysed by Mann-Whitney test, considering p-values <0.05 as 589 statistically significant (*p<0.05, **p< 0.01, ***p< 0.001, ****p<0.0001). (C) Boxplot 590 representation of infiltrating pDCs in controls (n=7), responder (n=6) and non-591 responder (n=7) pre-PPI and post-PPI. Relative count per mm², group median and 592 minimum and maximum values are represented. Differences were analysed by Mann-593 594 Whitney test, considering p-values <0.05 as statistically significant (*p<0.05, **p< 0.01, ***p< 0.001, ****p<0.0001). Responder (R), Non-Responder (NR), before treatment 595 (PrePPI), after treatment (PostPPI). (D) Pearson correlation between tissue eosinophil 596 597 count and tissue pDCs. Pearson correlation coefficient and p-value are shown. (E)

- 598 Pearson correlation between circulating pDC and tissue pDCs. Pearson correlation
- 599 coefficient and p-value are shown.

600

601 **DISCUSSION**

Using state-of-the-art spectral cytometry, we hereby describe, for the first time to our 602 603 knowledge, a unique fingerprint in the circulating immunome of patients with EoE at the 604 time of disease diagnosis characterized by a specific deficit of circulating pDCs. Indeed, their levels were further decreased at diagnosis in patients who did not 605 606 respond to PPI treatment, while among those who did, circulating levels of this cell subset were restored to normal levels upon treatment. Moreover, when we evaluated 607 608 the presence of pDCs in the esophagus their numbers correlated with the eosinophilic count, showing both an inverse correlation with circulating pDCs. Hence, our findings 609 610 suggest a central role of pDCs in the pathogenesis of EoE and reveal them as potential 611 novel non-invasive biomarkers to aid on disease diagnosis and predict subsequent response to PPI therapy. 612

In addition to our novel findings on pDCs, we found an increase in CD4⁻CD8⁻ T-cells and CD8⁺ Early Effectors (C-37 and C-69, respectively) in EoE patients at diagnosis, although these results could not be further confirmed by classical gating approaches. Increased levels of T-cells could be related with the active role of CD8⁺T cells in the esophageal inflammation in EoE^{30,31} while the change in CD4⁻CD8⁻ T-cells might be associated with their cytotoxic activity as described for other pathologies ³², despite no role for these cells has been found in EoE.

PPI therapy is widely used in the management of EoE^{16,33}, with a histologic remission 620 rate of approximately 50%¹⁶. The reduction in Th2 signalling produced by this therapy 621 622 leads to an improvement in the structural characteristics of the esophagus, 623 accompanied by decreased eosinophil count. In our study, non-responding patients 624 presented significant differences from responding patients (Figure 3A). When we 625 studied these two groups PrePPI intake, non-responding patients had lower levels of 626 pDCs, classical monocytes and an unknown myeloid APC cluster, but higher levels of non-memory B cells, mature NK cells and central memory CD4⁺ T-cells. These results 627 628 might indicate an increased antigen presentation activity, since they have decreased numbers of circulating APC populations, which are key in homeostasis and allergy 629 response³⁴. Indeed, latest results from our group³⁵ reinforce this hypothesis showing 630 that non-responding patients' esophageal proteomic profile when compared to 631 632 responding patients (both PrePPI), have increased levels of proteins associated with antigen presentation. These patients might have a more altered barrier in the 633 esophagus, which increases the risk of antigen exposure, thereby favouring EoE 634 worsening, as described before³⁶⁻³⁸. Although these findings need a deeper 635 characterization, they unveil for the first time a differential immunological profile 636 between patients that will or will not respond to PPI therapy and could open the door to 637 638 a better profiling of refractory patients.

639 In addition, when we studied immune dynamics during PPI treatment, PPI-responding patients displayed a significant increase in circulating basophils (C-14) and pDCs (C-640 26) (Figure 4A). Basophils have a pivotal role in atopic diseases and are a major 641 source of Th2 immunomodulation. The increased levels of these cells in patients who 642 643 achieve remission after PPI therapy could be related to the reestablishment of immunological homeostasis, since during inflammation basophils are able to penetrate 644 the inflamed esophagus ³⁹. A similar role may be played by circulating pDCs, which 645 recover control values in PPI-responding patients PostPPI (Figure 5A). pDCs produce 646 high levels of IFN- $\alpha\beta$ (type I). This cytokine impairs Th2 responses by blocking the 647

normal development of Th2 cells and production of Th2 cytokines (especially IL-5)^{40,41}.
 The reduction in circulating pDCs during active esophageal inflammation could be
 indicating migration of these cells to the inflamed tissue to control the inflammatory
 response. Conceivably, circulating levels of these cells are restored when the patient
 achieves remission.

Importantly, the chemokine receptors CXCR3 and CCR7 related to pDC migration to 653 tissues and homing to the LN^{28,29,42} were expressed in circulating pDCs (Figure 6A) in 654 655 our cohorts. Indeed, responders presented the most activated pDCs after PPI 656 treatment (Figure 5B) while no significant changes were found in the case of non-657 responding patients. Together with the previous results, the observed low levels of 658 pDCs in PrePPI and PostPPI non-responding patients (Figure 5A) and their less active 659 circulating profile (Figure 6B), could be linked to a poor inhibition of the Th2 response by type I IFN or/and a more exacerbated mucosal barrier alteration and therefore a 660 worse prognosis^{36,40}. 661

Focusing on promising minimally invasive biomarkers, pDCs are a potentially 662 663 interesting candidate since they are highly related with EoE onset and the response to 664 treatment. We have observed an inverse correlation between circulating pDCs and the peak eosinophil count in esophageal biopsies (Figure 5B). Moreover, when we 665 evaluated tissue pDC levels in patient's biopsies we found a positive correlation 666 between these cells and the proportion of eosinophils per mm² (Figure 7D), being also 667 inversely correlated to pDC circulating levels (Figure 7E). In patients, the number of 668 tissue pDCs was higher when the esophageal inflammation was active, reducing their 669 670 abundance when the inflammation was under control (Figure7C). However, Responder 671 patients do not reach control values after treatment despite pDC levels tend to be 672 lower. This could be due to a non-complete recovery state, in which these cells participate in the restoration of the esophageal homeostasis as happens in other 673 pathologies⁴³ where tissue healing plays a key role. Thus, it may be that the evaluation 674 675 of tissue pDC levels in long-term recovered patients would reveal closer numbers to 676 the control.

677 Hence, this population is related with the inflammatory status of the esophagus, thus 678 providing information of clinical diagnostic parameters that until now can only be 679 measured through invasive procedures. In peripheral blood, previous works have 680 related an increase in Th2 profile to active EoE⁴⁴, while others have associated this to eosinophil phenotype or maturation state^{45,46}. Also, single cell studies have described 681 T-cell heterogeneity in the inflamed tissue, defining a specific enrichment in resident 682 CD4⁺ T regulatory and Th2 effector cells together with an increased CD4⁺/CD8⁺ 683 circulating T-cell ratio ⁴⁷. Nevertheless, none of these parameters is being used as 684 biomarker for EoE diagnosis, or for the prediction of response to PPI treatment, for 685 686 which the peripheral eosinophil count has been proposed as a possible predictor⁴⁸.

We are aware that advances in biomarker discovery in EoE are hampered by several 687 pitfalls, such as the common concurrence of atopic diseases and the dissociation 688 between the esophageal inflammation and patient's symptoms²³. Accordingly, despite 689 our cohorts are highly controlled and paired samples from the same patients were 690 691 analysed, further studies and validations are needed to confirm the utility of circulating 692 pDCs as biomarker. The activity of this cluster must be compared in cohorts with other allergic and atopic conditions, since in these pathologies a decreased peripheral pDC 693 count was found, together with pDC infiltration in the inflamed tissue⁴⁹⁻⁵¹. Probably, its 694 695 visualization through classic cytometry approaches and its combination with other non-

invasive clinical parameters would be helpful to establish a specific signature for EoE
 management and PPI response prediction, also opening the door to study its utility in
 the case of other therapy options for EoE.

In summary, we have described, for the first time to our knowledge, the circulating immunome of EoE patients at the time of diagnosis highlighting as well the differences between PPI-responding and non-responding patients. Altogether, our study provides new insights on EoE immunity and sheds light on the characterization of this disorder, proposing a potential biomarker for diagnosis and prediction of response to treatment, which could improve decisions on better treatment options.

705

706 **REFERENCES**

- 707
- Navarro, P., Arias, Á., Arias-González, L., Laserna-Mendieta, E.J., Ruiz-Ponce, M., and
 Lucendo, A.J. (2019). Systematic review with meta-analysis: the growing incidence and
 prevalence of eosinophilic oesophagitis in children and adults in population-based
 studies. Aliment Pharmacol Ther 49, 1116–1125. 10.1111/APT.15231.
- Arias, Á., and Lucendo, A.J. (2019). Incidence and prevalence of eosinophilic
 oesophagitis increase continiously in adults and children in Central Spain: A 12-year
 population-based study. Dig Liver Dis *51*, 55–62. 10.1016/J.DLD.2018.07.016.
- Lucendo, A.J., Molina-Infante, J., Arias, Á., von Arnim, U., Bredenoord, A.J., Bussmann,
 C., Amil Dias, J., Bove, M., González-Cervera, J., Larsson, H., et al. (2017). Guidelines on
 eosinophilic esophagitis: evidence-based statements and recommendations for
 diagnosis and management in children and adults. United European Gastroenterol J 5,
 335–358. 10.1177/2050640616689525.
- Hirano, I., Chan, E.S., Rank, M.A., Sharaf, R.N., Stollman, N.H., Stukus, D.R., Wang, K.,
 Greenhawt, M., Falck-Ytter, Y.T., Chachu, K.A., et al. (2020). AGA Institute and the Joint
 Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the
 Management of Eosinophilic Esophagitis. Gastroenterology *158*, 1776–1786.
 10.1053/J.GASTRO.2020.02.038.
- 5. Schoepfer, A., and Safroneeva, E. (2014). Activity assessment of eosinophilic
 esophagitis. Dig Dis 32, 98–101. 10.1159/000357081.
- 7276.McCormick, J.P., and Lee, J.T. (2021). Insights into the Implications of Coexisting Type 2728Inflammatory Diseases. J Inflamm Res 14, 4259–4266. 10.2147/JIR.S311640.
- González-Cervera, J., Arias, Á., Redondo-González, O., Cano-Mollinedo, M.M.,
 Terreehorst, I., and Lucendo, A.J. (2017). Association between atopic manifestations
 and eosinophilic esophagitis: A systematic review and meta-analysis. Annals of Allergy,
 Asthma and Immunology *118*, 582-590.e2. 10.1016/j.anai.2017.02.006.
- Greuter, T., Alexander, J.A., Straumann, A., and Katzka, D.A. (2018). Diagnostic and
 Therapeutic Long-term Management of Eosinophilic Esophagitis—Current Concepts and
 Perspectives for Steroid Use. Clin Transl Gastroenterol *9*. 10.1038/S41424-018-0074-8.
- Molina-Infante, J., and Lucendo, A.J. (2017). Proton Pump Inhibitor Therapy for
 Eosinophilic Esophagitis: A Paradigm Shift. Am J Gastroenterol *112*, 1770–1773.
 10.1038/AJG.2017.404.

739	10.	Laserna-Mendieta, E.J., Casabona, S., Savarino, E., Perelló, A., Pérez-Martínez, I.,
740	10.	Guagnozzi, D., Barrio, J., Guardiola, A., Asensio, T., de la Riva, S., et al. (2020). Efficacy of
741		Therapy for Eosinophilic Esophagitis in Real-World Practice. Clin Gastroenterol Hepatol
742		<i>18</i> , 2903-2911.e4. 10.1016/J.CGH.2020.01.024.
743	11.	Molina-Infante, J., and Lucendo, A.J. (2020). Approaches to diet therapy for eosinophilic
744		esophagitis. Curr Opin Gastroenterol 36, 359–363. 10.1097/MOG.000000000000645.
745	12.	Molina-Infante, J., Bredenoord, A.J., Cheng, E., Dellon, E.S., Furuta, G.T., Gupta, S.K.,
746		Hirano, I., Katzka, D.A., Moawad, F.J., Rothenberg, M.E., et al. (2016). Proton pump
747		inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic
748		criteria for eosinophilic oesophagitis. Gut 65, 521–531. 10.1136/GUTJNL-2015-310991.
749	13.	Dellon, E.S., Rothenberg, M.E., Collins, M.H., Hirano, I., Chehade, M., Bredenoord, A.J.,
750		Lucendo, A.J., Spergel, J.M., Aceves, S., Sun, X., et al. (2022). Dupilumab in Adults and
751 752		Adolescents with Eosinophilic Esophagitis. N Engl J Med <i>387</i> , 2317–2330. 10.1056/NEJMOA2205982.
753	14.	Uchida, A.M., Burk, C.M., Rothenberg, M.E., Furuta, G.T., and Spergel, J.M. (2023).
754		Recent advances in the treatment of eosinophilic esophagitis. J Allergy Clin Immunol
755		Pract <i>0</i> . 10.1016/j.jaip.2023.06.035.
756	15.	Laserna-Mendieta, E.J., Navarro, P., Casabona-Francés, S., Savarino, E. V., Pérez-
757		Martínez, I., Guagnozzi, D., Barrio, J., Perello, A., Guardiola-Arévalo, A., Betoré-Glaria,
758 759		M.E., et al. (2023). Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry. Dig Liver Dis <i>55</i> , 350–359.
759 760		10.1016/J.DLD.2022.09.020.
761	16.	Laserna-Mendieta, E.J., Casabona, S., Guagnozzi, D., Savarino, E., Perelló, A., Guardiola-
762 763		Arévalo, A., Barrio, J., Pérez-Martínez, I., Lund Krarup, A., Alcedo, J., et al. (2020). Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients:
764		results from the EoE connect registry. Aliment Pharmacol Ther 52, 798–807.
765		10.1111/APT.15957.
766	17.	Van Rhijn, B.D., Warners, M.J., Curvers, W.L., Van Lent, A.U., Bekkali, N.L., Takkenberg,
767	±7.	R.B., Kloek, J.J., Bergman, J.J.G.H.M., Fockens, P., and Bredenoord, A.J. (2014).
768		Evaluating the endoscopic reference score for eosinophilic esophagitis: moderate to
769		substantial intra- and interobserver reliability. Endoscopy 46, 1049–1055. 10.1055/S-
770		0034-1377781.
771	18.	Lucendo, A.J., and Molina-Infante, J. (2016). Limitation of Symptoms as Predictors of
772		Remission in Eosinophilic Esophagitis: The Need to Go Beyond Endoscopy and
773		Histology. Gastroenterology <i>150</i> , 547–549. 10.1053/J.GASTRO.2016.01.014.
774	19.	Wen, T., Stucke, E.M., Grotjan, T.M., Kemme, K.A., Abonia, J.P., Putnam, P.E., Franciosi,
775		J.P., Garza, J.M., Kaul, A., King, E.C., et al. (2013). Molecular diagnosis of eosinophilic
776		esophagitis by gene expression profiling. Gastroenterology 145, 1289–1299.
777		10.1053/J.GASTRO.2013.08.046.
778	20.	Rochman, M., Wen, T., Kotliar, M., Dexheimer, P.J., Morgenstern, N.B.B., Caldwell, J.M.,
779		Lim, H.W., and Rothenberg, M.E. (2022). Single-cell RNA-Seq of human esophageal

780 781		epithelium in homeostasis and allergic inflammation. JCI Insight 7. 10.1172/JCI.INSIGHT.159093.
782 2 783 784	21.	Rochman, M., Azouz, N.P., and Rothenberg, M.E. (2018). Epithelial origin of eosinophilic esophagitis. Journal of Allergy and Clinical Immunology <i>142</i> , 10–23. 10.1016/J.JACI.2018.05.008.
785 2 786 787 788 789	22.	Molina-Jiménez, F., Ugalde-Triviño, L., Arias-González, L., Relaño-Rupérez, C., Casabona, S., Pérez-Fernández, M.T., Martín-Domínguez, V., Fernández-Pacheco, J., Laserna-Mendieta, E.J., Muñoz-Hernández, P., et al. (2023). Proteomic analysis of the esophageal epithelium reveals key features of eosinophilic esophagitis pathophysiology. Allergy. 10.1111/ALL.15779.
790 2 791 792	23.	Rossi, C.M., Lenti, M.V., and Di Sabatino, A. (2022). The need for a reliable non-invasive diagnostic biomarker for eosinophilic oesophagitis. Lancet Gastroenterol Hepatol 7, 202–203. 10.1016/S2468-1253(21)00468-4.
793 2 794 795 796	24.	Hirano, I., Moy, N., Heckman, M.G., Thomas, C.S., Gonsalves, N., and Achem, S.R. (2013). Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut <i>62</i> , 489–495. 10.1136/GUTJNL-2011-301817.
797 2 798 799 800 801	25.	Collins, M.H., Martin, L.J., Alexander, E.S., Todd Boyd, J., Sheridan, R., He, H., Pentiuk, S., Putnam, P.E., Abonia, J.P., Mukkada, V.A., et al. (2017). Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus <i>30</i> . 10.1111/DOTE.12470.
802 2 803 804	26.	Park, L.M., Lannigan, J., and Jaimes, M.C. (2020). OMIP-069: Forty-Color Full Spectrum Flow Cytometry Panel for Deep Immunophenotyping of Major Cell Subsets in Human Peripheral Blood. Cytometry A <i>97,</i> 1044–1051. 10.1002/CYTO.A.24213.
805 2 806	27.	McInnes, L., Healy, J., Saul, N., and Großberger, L. (2018). UMAP: Uniform Manifold Approximation and Projection. J Open Source Softw <i>3</i> , 861. 10.21105/JOSS.00861.
807 2 808 809 810	28.	Vanbervliet, B., Bendriss-Vermare, N., Massacrier, C., Homey, B., De Bouteiller, O., Brière, F., Trinchieri, G., and Caux, C. (2003). The Inducible CXCR3 Ligands Control Plasmacytoid Dendritic Cell Responsiveness to the Constitutive Chemokine Stromal Cell–derived Factor 1 (SDF-1)/CXCL12. J Exp Med <i>198</i> , 823. 10.1084/JEM.20020437.
811 2 812 813 814	29.	Seth, S., Oberdörfer, L., Hyde, R., Hoff, K., Thies, V., Worbs, T., Schmitz, S., and Förster, R. (2011). CCR7 Essentially Contributes to the Homing of Plasmacytoid Dendritic Cells to Lymph Nodes under Steady-State As Well As Inflammatory Conditions. The Journal of Immunology <i>186</i> , 3364–3372. 10.4049/JIMMUNOL.1002598.
815 3 816 817	30.	Anilkumar, A.A., Beppu, L., Kurten, R., Newbury, R., Dohil, R., Broide, D., and Aceves, S.S. (2014). CD3 and CD8 Cells Produce IL-9 In Pediatric Eosinophilic Esophagitis. Journal of Allergy and Clinical Immunology <i>133</i> , AB288. 10.1016/j.jaci.2013.12.1017.
818 3 819 820 821	31.	Abdolahi, M., Rasouli, S., Babaie, D., Dara, N., Imanzadeh, F., Sayyari, A., Rouhani, P., Khatami, K., Kazemiaghdam, M., Nilipour, Y., et al. (2021). Increased regulatory T cells in peripheral blood of children with eosinophilic esophagitis. Gastroenterol Hepatol Bed Bench <i>14</i> , 25–30.

822 823 824	32.	Wu, Z., Zheng, Y., Sheng, J., Han, Y., Yang, Y., Pan, H., and Yao, J. (2022). CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer. Front Immunol <i>13</i> , 388. 10.3389/FIMMU.2022.816005/BIBTEX.
825 826 827 828	33.	Chang, J.W., Saini, S.D., Mellinger, J.L., Chen, J.W., Zikmund-Fisher, B.J., and Rubenstein, J.H. (2019). Management of eosinophilic esophagitis is often discordant with guidelines and not patient-centered: results of a survey of gastroenterologists. Dis Esophagus <i>32</i> . 10.1093/DOTE/DOY133.
829 830 831	34.	Schülke, S., Gilles, S., Jirmo, A.C., and Mayer, J.U. (2023). Tissue-specific antigen-presenting cells contribute to distinct phenotypes of allergy. Eur J Immunol, 2249980. 10.1002/EJI.202249980.
832 833 834 835 836 837	35.	Molina-Jiménez, F., Ugalde-Triviño, L., Arias-González, L., Relaño-Rupérez, C., Casabona, S., Moreno-Monteagudo, J.A., Pérez-Fernández, M.T., Martín-Domínguez, V., Fernández-Pacheco, J., Laserna-Mendieta, E.J., et al. (2023). Proton pump Inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction and evaluation of treatment response. medRxiv, 2023.11.21.23298292. 10.1101/2023.11.21.23298292.
838 839 840	36.	Chen, J., Oshima, T., Huang, X., Tomita, T., Fukui, H., and Miwa, H. (2022). Esophageal Mucosal Permeability as a Surrogate Measure of Cure in Eosinophilic Esophagitis. J Clin Med 11. 10.3390/JCM11144246.
841 842 843 844	37.	Furuta, G.T., Fillon, S.A., Williamson, K.M., Robertson, C.E., Stevens, M.J., Aceves, S.S., Arva, N.C., Chehade, M., Collins, M.H., Davis, C.M., et al. (2023). Mucosal Microbiota Associated With Eosinophilic Esophagitis and Eosinophilic Gastritis. J Pediatr Gastroenterol Nutr <i>76</i> , 347–354. 10.1097/MPG.000000000003685.
845 846 847 848	38.	Kleuskens, M.T.A., Bek, M.K., Al Halabi, Y., Blokhuis, B.R.J., Diks, M.A.P., Haasnoot, M.L., Garssen, J., Bredenoord, A.J., C.A.M. van Esch, B., and Redegeld, F.A. (2023). Mast cells disrupt the function of the esophageal epithelial barrier. Mucosal Immunol. 10.1016/J.MUCIMM.2023.06.001.
849 850 851	39.	Marković, I., and Savvides, S.N. (2020). Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer. Front Immunol <i>11</i> . 10.3389/FIMMU.2020.01557.
852 853 854 855	40.	Pritchard, A.L., Carroll, M.L., Burel, J.G., White, O.J., Phipps, S., and Upham, J.W. (2012). Innate IFNs and Plasmacytoid Dendritic Cells Constrain Th2 Cytokine Responses to Rhinovirus: A Regulatory Mechanism with Relevance to Asthma. The Journal of Immunology <i>188</i> , 5898–5905. 10.4049/JIMMUNOL.1103507.
856 857 858	41.	Lin, J.Y., Wu, W.H., Chen, J.S., Liu, I.L., Chiu, H.L., Chen, H.W., Tsai, T.L., Huang, Y.L., and Wang, L.F. (2020). Plasmacytoid dendritic cells suppress Th2 responses induced by epicutaneous sensitization. Immunol Cell Biol <i>98</i> , 215–228. 10.1111/IMCB.12315.
859 860 861 862	42.	Kohrgruber, N., Gröger, M., Meraner, P., Kriehuber, E., Petzelbauer, P., Brandt, S., Stingl, G., Rot, A., and Maurer, D. (2004). Plasmacytoid Dendritic Cell Recruitment by Immobilized CXCR3 Ligands. The Journal of Immunology <i>173</i> , 6592–6602. 10.4049/JIMMUNOL.173.11.6592.

863 864 865 866	43.	Gregorio, J., Meller, S., Conrad, C., Di Nardo, A., Homey, B., Lauerma, A., Arai, N., Gallo, R.L., DiGiovanni, J., and Gilliet, M. (2010). Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J Exp Med <i>207</i> , 2921. 10.1084/JEM.20101102.
867 868 869 870	44.	Adel-Patient, K., Campeotto, F., Grauso, M., Guillon, B., Moroldo, M., Venot, E., Dietrich, C., Machavoine, F., Castelli, F.A., Fenaille, F., et al. (2023). Assessment of local and systemic signature of eosinophilic esophagitis (EoE) in children through multi-omics approaches. Front Immunol 14. 10.3389/FIMMU.2023.1108895.
871 872 873 874	45.	Perez-Lucendo, I., Gomez Torrijos, E., Donado, P., Melero, R., Feo-Brito, F., and Urra, J.M. (2021). Low Expression of ICAM-1 in Blood Eosinophils in Patients With Active Eosinophilic Esophagitis. J Investig Allergol Clin Immunol <i>31</i> , 316–321. 10.18176/JIACI.0489.
875 876 877 878	46.	Henderson, A., Magier, A., Schwartz, J.T., Martin, L.J., Collins, M.H., Putnam, P.E., Mukkada, V.A., Abonia, J.P., Rothenberg, M.E., and Fulkerson, P.C. (2020). Monitoring Eosinophilic Esophagitis Disease Activity With Blood Eosinophil Progenitor Levels. J Pediatr Gastroenterol Nutr <i>70</i> , 482–488. 10.1097/MPG.000000000002583.
879 880 881 882	47.	Wen, T., Aronow, B.J., Rochman, Y., Rochman, M., Kiran, K.C., Dexheimer, P.J., Putnam, P., Mukkada, V., Foote, H., Rehn, K., et al. (2019). Single-cell RNA sequencing identifies inflammatory tissue T cells in eosinophilic esophagitis. J Clin Invest <i>129</i> , 2014–2028. 10.1172/JCI125917.
883 884 885 886	48.	Alexander, R., Alexander, J.A., Akambase, J., Harmsen, W.S., Geno, D., Tholen, C., Katzka, D.A., and Ravi, K. (2021). Proton Pump Inhibitor Therapy in Eosinophilic Esophagitis: Predictors of Nonresponse. Dig Dis Sci <i>66</i> , 3096–3104. 10.1007/S10620- 020-06633-4.
887 888 889 890	49.	Albanesi, C., Scarponi, C., Pallotta, S., Daniele, R., Bosisio, D., Madonna, S., Fortugno, P., Gonzalvo-Feo, S., Franssen, J.D., Parmentier, M., et al. (2009). Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med <i>206</i> , 249–258. 10.1084/JEM.20080129.
891 892 893	50.	Saadeh, D., Kurban, M., and Abbas, O. (2016). Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases. Exp Dermatol <i>25</i> , 415–421. 10.1111/EXD.12957.
894 895 896 897	51.	Charles, J., Chaperot, L., Salameire, D., Domizio, J. Di, Aspord, C., Gressin, R., Jacob, M C., Richard, MJ., Beani, JC., Plumas, J., et al. (2010). Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer. Eur J Dermatol <i>20</i> , 16. 10.1684/EJD.2010.0816.
898		
899 900 901 902	Repr total	Dementary Figure 1. Hierarchical gating strategy for cluster classification. esentative gating strategy used to identify the main leukocyte populations within peripheral blood mononuclear cells (PBMC). Arrows and gates are used to

visualize the relationships across plots. After doublets and dead cells were excluded,

basophils were identified as CD45+CD123+CD38+ cells. Monocytes were gated based

904 on FSC-A/SSC-A properties and further classified into non-classical (CD14–CD16+),

intermediate (CD14+CD16+/low), and classical (CD14+CD16-). Within the lymphocyte 905 gate, T-cells were identified based on the expression of CD3. Total vo T-cells were 906 907 identified as CD3+ $y\delta$ T-cell receptor (TCR)+ and subdivided based on the expression 908 of CD45RA and CCR7. Total NKT-like cells were identified in the CD3+yδTCR-909 compartment as CD56+. The inclusion of CD2 and CD8 further classified the NKT-like cells. Total T-cells were defined as CD3+yδTCR-CD56- and further divided into CD4+, 910 911 CD8+, CD4+CD8+ and CD4-CD8- T-cells. Within total CD4+ T-cells and CD8+ T-912 cells, CCR7, CD45RA, CD27, and CD28 were further used to divide them into different 913 T-cell phenotypes. B-cells were gated from the CD3-γδTCR- as CD19+ and/or CD20+ 914 cells. B-cells were further classified as IgD+CD27-, IgD+CD27+, or IgD-CD27+/-; the 915 IgD-CD27+/- subset was divided into plasmablasts or IgD- memory B cells based on CD20 expression and CD27. Memory cells were classified into IgM+ or IgG+. NK cells 916 917 were defined within the lymphocyte gate as CD3-γδTCR- and classified as early NK 918 (CD56+CD16-), mature NK (CD56+CD16+), and terminal NK (CD56-CD16+) cells. 919 Dendritic cells were identified within CD3-CD19- as CD14-CD16-. Further gating 920 identified CD123+CD45RA+ cells as plasmacytoid DCs, (pDC) and CD123-CD11c+ as 921 classical or conventional DC (cDC). cDC were divided into type 1 (CD141+, cDC1) and 922 type 2 (CD1c+, cDC2).

923

Supplementary Figure 2. Gating strategy for significant cluster validation. Statistically 924 925 significant cell clusters identified in Table 1 among the different comparisons performed 926 were further validated by identification following classical hierarchical gating approaches. C-56 was gated from central memory CD4+ CD127+ cells. C-69 was 927 928 identified from early CD8 effectors as CD38+ CD314+ PD1+ CXCR3+CD95+ cells. C-929 37 was identified from CD8-CD4- cells as CD314+ CD45RA+ CD2+ CD159a+. C-4 930 subset was identified as mature NK CD45RA+ CD314+ CD14+ CCR5+ CD2+ CD57+ 931 CD159a+ cells. C-22 was gated from non-memory CD27- cell as IgM+ CXCR3- cells. 932 C-26 was defined as CD38+ CD141+ CD4+ CCR5+. C-27 was classified from classical 933 monocytes as IgG+ CD38+ CD39+ CXCR3+ CD95+ cells. C-33 was gated as CD19-934 CD3- CD14- CD56- CXCR3+ CCR7+. C-14 was defined as CXCR3+ CD38+ basophils.

935

Supplementary Figure 3. Marker expression on the UMAP from peripheral blood
mononuclear cells. Surface expression intensities of all 37 analysed markers are
shown by a colour code based on the intensity. Red represents higher expression and
blue represents lower expression

940

941 Supplementary Figure 4. Non-Responders do not recover pDC values after 942 treatment. (A) Volcano plot of differential analysis between NR-PrePPI (n=9) and NR-943 PostPPI (n=9). LogFC and -Log(p-value) are represented. (B) UMAP representation from NR-PrePPI and PostPPI patients with pDC coloured. (C) Validation by classic 944 gating of pDC as shown in Supplementary Figures 1 and 2. Boxplot with pDC 945 946 represents individual percentage of total value, group median and minimum and 947 maximum values. Red line indicates paired PrePPI and PostPPI samples. Differences 948 were analysed by paired t-test analysis considering p-values <0.05 as statistically

significant (*p<0.05) (n=7). Non-Responder (NR), before treatment (PrePPI), after
 treatment (PostPPI).

952 Supplementary Table 1. Specificity, fluorochrome, clone and provider of the different953 antibodies used.


Supplementary Table 2. Cell cluster identification from control and EoE patients. For


each of the 73 identified FlowSOM clusters its ontogeny and subset is shown, togetherwith the specific subset, phenotype and expression of functional markers. Markers

with the specific subset, phenotype and expression of functional markers. Markershighlighted in bold denote differential expression within the same population.




C-26 Denditic cells pDC





В



Q4 CCR7- / CXCR3-

0 104

1000 80

-10

-10

Q1 CCR7- / CXCR3

10^s

PE-Cy7-A | CXCR3

Q4 CCR7- / CXCR3

104

.....

10* 0

10


Q1 CCR7- / CXCR3+

105

PE-Cy7-A | CXCR3

1.2K


В




A MERGE


10<u>u</u>m


В



















Ε





	Control (n=19)	EoE (n=25)	p-value	Responders (n=9)	Non-Responders (n=9)	p-value
Sex (male) (n,%)	13 (68%)	20 (80%)	0.488	7 (77%)	7 (77%)	1
Age (mean years ± s.d.)	34.42 ± 10.93	41 ± 13.7	0.060	33 ± 12.85	44 ± 14.95	0.152
Symptoms (n,%)						
Dysphagia	0	23 (92%)	<0.001	9 (100%)	9 (100%)	1
Food impaction	0	16 (64%)	<0.001	7 (77%)	5 (55%)	0.619
Heartburn	0	10 (40%)	0.002	3 (33%)	3 (33%)	1
Abdominal pain	0	0 (0%)	1	0 (0%)	0 (0%)	1
Any atopic disease (n,%)						
Asthma	0	5 (22%)	0.053	3 (33%)	1 (11%)	0.573
Allergic rhinitis/sinusitis	1 (5%)	19 (82%)	<0.001	8 (88%)	9 (100%)	1
Food allergy	2 (10%)	11 (48%)	0.0173	5 (55%)	3 (33%)	0.637
Endoscopic findings (n,%)						
EREFS (mean ± s.d.)	0	3.36 ± 2	<0.001	2.44 ± 2.06	3.88 ± 1.26	0.097
EREFS PostPPI (mean ± s.d.)	-	-	-	1.44± 1.51	4.33± 1	<0.001
Maximum eosinophil count (mean ± s.d.)	0	55.68 ± 23.9	<0.001	46.22 ± 21.76	65.56 ± 19.43	0.064
Maximum eosinophil count PostPPI (mean ± s.d.)	-	-	-	1.44 ± 2	65 ± 20.91	<0.001
Histological findings						
EoEHSS Grade (0-1)	0	0.50 ± 0.19	<0.001	0.43 ± 0.22	0.57 ± 0.15	0.122
(mean ± s.d.)						
EoEHSS Grade (0-1) PostPPI (mean ± s.d.)	-	-	-	0.06 ± 0.04	0.40 ± 0.22	0.006
EoEHSS Stage (0-1) (mean ± s.d.)	0	0.47 ± 0.16	<0.001	0.43 ± 0.17	0.57 ± 0.15	0.122
EoEHSS Stage (0-1) PostPPI (mean ± s.d.)	-	-	-	0.02 ± 0.03	0.31 ± 0.19	0.007
PPI Treatment						
Omeoprazol	-	-	-	6 (66%)	2 (22%)	0.1385
Esomeprazol				2 (22%)	2 (22%)	
Pantoprazol				1 (11%)	5 (55%)	


B














 C-1 NK Mature (1) C-2 NK Mature (2) C-3 NK Mature (3) C-4 NK Mature (4)
C-5 NK Mature (5)
C-6 NK Mature (6)
C-7 NK Mature (7)
C-8 NK Early to Mature
C-9 NK Early (1)
C-10 NK Early (2)
C-11 NK Early (3)
C-12 NK Early (4)
C-13 Unknown
C-14 Basophil
C-15 B Memory
C-16 B Memory IgG*
C-17 B Memory IgM*(1) C-18 B Memory IgM*(2)
C-19 B No Memory CD27(1)
C-20 B No Memory CD27 (1)
C-20 B No Memory CD27 (2) C-21 B No Memory CD27 (3)
C-22 B No Memory CD27 (3)
C-23 Dendritic cells DC2(1)
C-24 Dendritic cells DC2(1)
C-25 Dendritic cells DC1
C-26 Dendritic cells pDC
C-27 Monocytes Classical (1)
C-28 Monocytes Classical (2)
C-29 Monocytes Classical (3)
C-30 Monocytes Classical (4)
C-31 Monocytes Non-Classical
C-32 Unknown Mieloid APC(1)
C-33 Unknown Mieloid APC(2)


C-34 NKT-Like CD2* CCR7 C-35 CD4 CD8* C-35 CD4 CD8(1) C-37 CD4 CD8(2) C-37 CD4 CD8(2) C-37 CD4 CD8(3) C-37 CD4 CD8(3) C-37 CD4 CD8(6) C-38 CD4 CD8(6) C-39 CD4 CD8(6) C-40 CD4 CD8(6) C-41 CD4 CD8(6) C-42 CD4 CD8(6) C-42 CD4 CD8(6) C-44 Terminal Effector CD4* CD45RA* like (1) C-45 Terminal Effector CD4* CD45RA* like (2) C-46 Terminal Effector CD4* (2) C-48 T CD4* Naive (1) C-47 Terminal Effector CD4* (2) C-48 T CD4* Naive (3) C-55 T CD4* Naive (3) C-55 Early Effector CD4* (2) C-55 Early Effector CD4* (2) C-55 Early Effector CD4* (2) C-55 Early Effector CD4* (2) C-55 Early Effector CD4* (2) C-56 Central Memory CD4* (2) C-57 CD4* Naive (1) C-58 Central Memory CD4* (2) C-58 Terminal Effector CD4* CD45RA* (1) C-64 Terminal Effector CD4* CD45RA* (1) C-64 Terminal Effector CD4* CD45RA* (2) C-58 Terminal Effector CD4* CD45RA* (3) C-59 Central Memory CD4* (2) C-58 Terminal Effector CD4* CD45RA* (3) C-59 Central Memory CD4* (2) C-59 Central Memory CD4* (2) C-59 Central Memory CD4* (2) C-59 Central Memory CD4* (3) C-59 Central Memory CD4* (3) C-59 Central Memory CD4* (3) C-59 Central Memory CD4* (2) C-59 Central Memory CD4* (2) C-59 Central Memory CD4* (2) C-59 Central Memory CD4* (2) C-59 Central Memory CD4* (3) C-59 Central Memory CD4* CD4* CD4* CD4* CD4* CD4* CD4* CD4*		
C-35 CD4' CD8' C-37 CD4' CD8' C-37 CD4' CD8'(1) C-37 CD4' CD8(2) C-70 Early Effector CD8'(3) C-37 CD4' CD8(2) C-71 Early Effector CD8'(4) C-38 CD4' CD8(3) C-40 CD4' CD8(5) C-40 CD4' CD8(5) C-41 CD4' CD8'(6) C-42 CD4' CD8'(6) C-42 CD4' CD8'(7) C-43 Työ CD45RA' CCR7 C-44 Terminal Effector CD4' CD45RA' like (1) C-45 Terminal Effector CD4' CD45RA' like (2) C-47 Terminal Effector CD4' (2) C-48 TCD4' Naive (1) C-47 Terminal Effector CD4' (2) C-51 T CD4' Naive (3) C-52 Early Effector CD4' (1) C-54 Early Effector CD4' (2) C-55 Early Effector CD4' (3) C-55 Central Memory CD4' (3) C-56 Contral Memory CD4' (3) C-57 CD8' Naive (2) C-58 T CD8' Naive (2) C-59 T CD8' Naive (2) C-50 T CD8' Naive (2) C-51 T CD8' Naive (2) C-51 T CD8' Naive (2) C-52 Early Effector CD4' (3) C-56 Central Memory CD4' (3) C-57 CD8' Naive (2) C-51 T T CD8' Naive (2) C-5	C-34 NKT-Like CD2 ⁺ CCR7 ⁻	C-68 Early Effector CD8 ⁺ (2)
 C-36 CD4 : CD8 : (1) C-37 CD4 : CD8 : (2) C-37 CD4 : CD8 : (3) C-71 Early Effector CD8 : (6) C-38 CD4 : CD8 : (3) C-71 Early Effector CD8 : (6) C-38 CD4 : CD8 : (5) C-40 CD4 : CD8 : (5) C-41 CD4 : CD8 : (6) C-42 CD4 : CD8 : (7) C-43 Työ CD45RA : CCR7 C-44 Terminal Effector CD4 : CD45RA : like (2) C-46 Terminal Effector CD4 : CD45RA : like (2) C-47 Terminal Effector CD4 : CD45RA : like (2) C-48 T CD4 : Naive (1) C-49 T CD4 : Naive (3) C-54 Early Effector CD4 : (1) C-54 Early Effector CD4 : (2) C-55 Early Effector CD4 : (2) C-56 Central Memory CD4 : (1) C-57 Central Memory CD4 : (2) C-58 Central Memory CD4 : (3) C-59 T CD8 : Naive (2) C-61 Terminal Effector CD8 : CD45RA : (1) C-62 Terminal Effector CD8 : CD45RA : (2) 	C-35 CD4 ⁺ CD8 ⁺	
C-37 CD4 CD8 ² (2) C-37 Early Effector CD8 ⁺ (5) C-38 CD4 CD8(3) C-72 Early Effector CD8 ⁺ (6) C-39 CD4 CD8(4) C-73 Early Effector CD8 ⁺ (6) C-40 CD4 CD8(6) C-40 CD4 CD8(6) C-42 CD4 CD8(7) C-44 Terminal Effector CD4 ⁺ (2) C-45 Terminal Effector CD4 ⁺ (2) C-46 Terminal Effector CD4 ⁺ (1) C-47 Terminal Effector CD4 ⁺ (1) C-47 Terminal Effector CD4 ⁺ (1) C-48 Terminal Effector CD4 ⁺ (1) C-49 T CD4 ⁺ Naive (1) C-49 T CD4 ⁺ Naive (2) C-50 T CD4 ⁺ Naive (3) C-51 T CD4 ⁺ Naive (4) C-52 Early Effector CD4 ⁺ (1) C-54 Early Effector CD4 ⁺ (1) C-54 Early Effector CD4 ⁺ (1) C-56 Central Memory CD4 ⁺ (2) C-58 Central Memory CD4 ⁺ (3) C-59 T CD8 ⁺ Naive (2) C-61 Terminal Effector CD8 ⁺ CD45RA ⁺ (1) C-62 Terminal Effector CD8 ⁺ CD45RA ⁺ (1) C-62 Terminal Effector CD8 ⁺ CD45RA ⁺ (2) C-61 Terminal Effector CD8 ⁺	C-36 CD4 ⁻ CD8 ⁻ (1)	
C-38 CD4 CD8(3) C-72 Ean ⁴ Effector CD8 ⁺ (6) C-30 CD4 CD8(4) C-73 Ean ⁴ Effector CD8 ⁺ (6) C-40 CD4 CD8(5) C-41 CD4 CD8(6) C-42 CD4 CD8(7) C-43 Ty ⁶ CD45RA ⁺ CCR ⁷ C-44 Terminal Effector CD4 ⁺ CD45RA ⁺ like (1) C-45 Terminal Effector CD4 ⁺ CD45RA ⁺ like (2) C-46 Terminal Effector CD4 ⁺ (2) C-47 Terminal Effector CD4 ⁺ (2) C-47 Terminal Effector CD4 ⁺ (2) C-48 T CD4 ⁺ Naive (1) C-47 Terminal Effector CD4 ⁺ (2) C-48 T CD4 ⁺ Naive (2) C-50 T CD4 ⁺ Naive (3) C-52 Ean ⁴ Effector CD4 ⁺ (2) C-54 Ean ⁴ Effector CD4 ⁺ (2) C-54 Ean ⁴ Effector CD4 ⁺ (2) C-55 Ean ⁴ Effector CD4 ⁺ (3) C-56 Central Memory CD4 ⁺ (3) C-57 CD8 ⁺ Naive (1) C-58 Central Memory CD4 ⁺ (2) C-59 T CD8 ⁺ Naive (2) C-61 Terminal Effector CD8 ⁺ CD45RA ⁺ (1) C-62 Terminal Effector CD8 ⁺ CD45RA ⁺ (2) C-63 Terminal Effector CD8 ⁺ CD45RA ⁺ (2) C-64 Terminal Effector CD8 ⁺ CD45RA ⁺ (3) C-64 Terminal Effector CD8 ⁺ CD45RA ⁺ (2) C-64 Terminal Effector CD8 ⁺ CD45RA ⁺ (3) C-64 Terminal Effector CD8 ⁺	C-37 CD4 CD8 (2)	
 C-39 CD4 : CD8'(4) C-30 Ed4 : CD8'(5) C-41 CD4 : CD8'(6) C-41 CD4 : CD8'(6) C-42 CD4 : CD8'(7) C-43 Terminal Effector CD4': CD45RA' like (1) C-44 Terminal Effector CD4': CD45RA' like (2) C-46 Terminal Effector CD4': CD45RA' like (2) C-46 Terminal Effector CD4': CD45RA' like (2) C-46 Terminal Effector CD4': CD45RA' like (2) C-47 Terminal Effector CD4': CD45RA' like (2) C-47 Terminal Effector CD4': CD45RA' like (2) C-48 T CD4': Naive (1) C-49 T CD4': Naive (2) C-51 T CD4': Naive (3) C-52 Early Effector CD4': (2) C-54 Early Effector CD4': (2) C-56 Central Memory CD4': (2) C-58 T CD8': Naive (2) C-61 Terminal Effector CD8': CD45RA': (1) C-62 Terminal Effector CD8': CD45RA': (2) C-63 Terminal Effector CD8': CD45RA': (2) 	C-38 CD4 CD8 (3)	
 C-40 CD4 : CD8'(5) C-41 CD4 : CD8'(6) C-42 CD4 : CD8'(7) C-43 Työ CD4SRA' CCR7 C-44 Terminal Effector CD4' CD4SRA' like (1) C-45 Terminal Effector CD4' (1) C-47 Terminal Effector CD4' (2) C-48 T CD4' Naive (2) C-49 T CD4' Naive (2) C-51 T CD4' Naive (2) C-52 Early Effector CD4' (1) C-52 Early Effector CD4' (2) C-54 Early Effector CD4' (2) C-55 Central Memory CD4' (2) C-55 Central Memory CD4' (3) C-55 Central Memory CD4' (3) C-56 Central Memory CD4' (3) C-57 CD8' Naive (2) C-61 Terminal Effector CD8' CD4SRA' (1) C-62 Terminal Effector CD8' CD4SRA' (2) 	C-39 CD4 ⁻ CD8 ⁻ (4)	
 C-42 CD4 : CD8'7) C-43 Työ CD45RA * CCR7 C-44 Terminal Effector CD4 * CD45RA * like (1) C-45 Terminal Effector CD4 * (1) C-46 Terminal Effector CD4 * (1) C-47 Terminal Effector CD4 * (2) C-48 TC D4 * Naive (1) C-49 T CD4 * Naive (2) C-50 T CD4 * Naive (3) C-51 T CD4 * Naive (4) C-52 Early Effector CD4 * (1) C-54 Early Effector CD4 * (2) C-55 Central Memory CD4 * (2) C-55 Central Memory CD4 * (3) C-56 Central Memory CD4 * (3) C-57 CD8 * Naive (2) C-61 Terminal Effector CD8 * CD45RA * (1) C-62 Terminal Effector CD8 * CD45RA * (2) 	C-40 CD4 CD8 (5)	,,
 C-43 Työ CD4SRÅ·CCR7⁻ C-44 Terminal Effector CD4⁺ CD45RA⁺ like (1) C-45 Terminal Effector CD4⁺ CD45RA⁺ like (2) C-46 Terminal Effector CD4⁺ (2) C-47 TCM⁺ Naive (1) C-49 TCD4⁺ Naive (3) C-51 TCD4⁺ Naive (3) C-51 TCD4⁺ Naive (3) C-52 Early Like Effector CD4⁺ (1) C-53 Early Effector CD4⁺ (1) C-54 Early Effector CD4⁺ (1) C-56 Central Memory CD4⁺ (2) C-57 CDB⁺ Naive (2) C-58 Central Memory CD4⁺ (2) C-59 TCD8⁺ Naive (2) C-61 Terminal Effector CD8⁺ CD45RA⁺ (1) C-62 Terminal Effector CD8⁺ CD45RA⁺ (2) C-63 Terminal Effector CD8⁺ CD45RA⁺ (3) 	C-41 CD4 CD8 (6)	
 C-44 Terminal Effector CD4* CD45RA* like (1) C-45 Terminal Effector CD4* CD45RA* like (2) C-46 Terminal Effector CD4* (1) C-47 Terminal Effector CD4* (2) C-48 T CD4* Naive (1) C-49 T CD4* Naive (2) C-50 T CD4* Naive (3) C-51 T CD4* Naive (3) C-51 T CD4* Naive (3) C-52 Early Effector CD4* (1) C-53 Early Effector CD4* (2) C-54 Early Effector CD4* (2) C-56 Central Memory CD4* (2) C-57 Central Memory CD4* (3) C-59 T CD8* Naive (2) C-61 Terminal Effector CD8* CD45RA* (1) C-62 Terminal Effector CD8* CD45RA* (3) 	C-42 CD4 CD8 (7)	
 C-45 Terminal Effector CD4* CD45RA* like (2) C-46 Terminal Effector CD4* (1) C-47 Terminal Effector CD4* (2) C-48 T CD4* Naive (2) C-47 TCD4* Naive (2) C-50 T CD4* Naive (2) C-51 T CD4* Naive (4) C-52 Early Like Effector CD4* (2) C-55 Early Effector CD4* (2) C-55 Early Effector CD4* (2) C-55 Early Effector CD4* (2) C-55 Central Memory CD4* (1) C-56 Central Memory CD4* (2) C-57 Central Memory CD4* (3) C-59 T CD8* Naive (2) C-61 Terminal Effector CD8* CD45RA* (1) C-62 Terminal Effector CD8* CD45RA* (3) 	C-43 Τγδ CD45RA* CCR7 ⁻	
 C-46 Terminal Effector CD4* (1) C-47 Terminal Effector CD4* (2) C-48 T CD4* Naive (1) C-49 T CD4* Naive (2) C-50 T CD4* Naive (3) C-51 T CD4* Naive (3) C-52 Early Like Effector CD4* C-53 Early Effector CD4* (1) C-54 Early Effector CD4* (2) C-55 Early Effector CD4* (3) C-56 Central Memory CD4* (1) C-57 Central Memory CD4* (2) C-58 Central Memory CD4* (3) C-59 T CD8* Naive (2) C-61 Terminal Effector CD8* CD45RA* (1) C-62 Terminal Effector CD8* CD45RA* (2) 	C-44 Terminal Effector CD4* CD45RA* like	(1)
 C-47 Terminal Effector CD4* (2) C-48 T CD4* Naive (2) C-50 T CD4* Naive (2) C-51 T CD4* Naive (3) C-51 T CD4* Naive (4) C-52 Early Effector CD4* (1) C-54 Early Effector CD4* (2) C-55 Central Memory CD4* (3) C-56 Central Memory CD4* (3) C-57 Central Memory CD4* (3) C-59 T CD8* Naive (2) C-61 Terminal Effector CD8* CD45RA* (1) C-62 Terminal Effector CD4* CD45RA* (3) 	C-45 Terminal Effector CD4* CD45RA* like	(2)
 C-48 T CD4' Naive (1) C-49 T CD4' Naive (2) C-50 T CD4' Naive (3) C-51 T CD4' Naive (4) C-52 Early Like Effector CD4' C-53 Early Effector CD4' (1) C-54 Early Effector CD4' (2) C-56 Central Memory CD4' (1) C-56 Central Memory CD4' (2) C-58 Central Memory CD4' (2) C-58 Central Memory CD4' (2) C-59 T CD8' Naive (1) C-60 T CD8' Naive (2) C-61 Terminal Effector CD8' CD45RA' (1) C-62 Terminal Effector CD8' CD45RA' (2) C-63 Terminal Effector CD8' CD45RA' (3) 	C-46 Terminal Effector CD4* (1)	
 C-49 T CD4' Naive (2) C-50 T CD4' Naive (3) C-51 T CD4' Naive (4) C-52 Early Like Effector CD4' C-53 Early Effector CD4' (1) C-54 Early Effector CD4' (2) C-56 Central Memory CD4' (2) C-56 Central Memory CD4' (2) C-57 Central Memory CD4' (3) C-59 T CD8' Naive (1) C-60 T CD8' Naive (2) C-61 Terminal Effector CD8' CD45RA' (1) C-62 Terminal Effector CD8' CD45RA' (3) 	C-47 Terminal Effector CD4* (2)	
 C-50 T CD4' Naive (3) C-51 T CD4' Naive (4) C-52 Early Like Effector CD4' C-53 Early Effector CD4' (1) C-54 Early Effector CD4' (2) C-55 Central Memory CD4' (2) C-56 Central Memory CD4' (2) C-58 Central Memory CD4' (2) C-58 Central Memory CD4' (3) C-59 T CD8' Naive (1) C-61 Terminal Effector CD8' CD45RA' (1) C-62 Terminal Effector CD8' CD45RA' (2) C-63 Terminal Effector CD8' CD45RA' (3) 	C-48 T CD4* Naive (1)	
 C-51 T CD4' Naive (4) C-52 Early Like Effector CD4' C-53 Early Effector CD4' (1) C-54 Early Effector CD4' (2) C-55 Early Effector CD4' (3) C-56 Central Memory CD4' (1) C-57 Central Memory CD4' (2) C-58 Central Memory CD4' (3) C-59 T CD8' Naive (1) C-60 T CD8' Naive (2) C-61 Terminal Effector CD8' CD45RA' (1) C-62 Terminal Effector CD8' CD45RA' (2) 	C-49 T CD4* Naive (2)	
 C-52 Early Like Effector CD4' C-53 Early Effector CD4' (1) C-54 Early Effector CD4' (2) C-55 Early Effector CD4' (3) C-56 Central Memory CD4' (1) C-57 Central Memory CD4' (2) C-58 Central Memory CD4' (3) C-59 T CD8' Naive (1) C-60 T CD8' Naive (2) C-61 Terminal Effector CD8' CD45RA' (1) C-62 Terminal Effector CD8' CD45RA' (3) 	C-50 T CD4* Naive (3)	
 C-53 Early Effector CD4' (1) C-54 Early Effector CD4' (2) C-55 Early Effector CD4' (3) C-56 Central Memory CD4' (1) C-57 Central Memory CD4' (2) C-58 Central Memory CD4' (3) C-59 T CD8' Naive (1) C-60 T CD8' Naive (2) C-61 Terminal Effector CD8' CD45RA' (1) C-62 Terminal Effector CD8' CD45RA' (2) C-63 Terminal Effector CD8' CD45RA' (3) 	C-51 T CD4* Naive (4)	
 C-54 Early Effector CD4' (2) C-55 Early Effector CD4' (3) C-56 Central Memory CD4' (1) C-57 Central Memory CD4' (2) C-58 Echtral Memory CD4' (3) C-59 T CD8' Naive (1) C-60 T CD8' Naive (2) C-61 Terminal Effector CD8' CD45RA' (1) C-62 Terminal Effector CD8' CD45RA' (2) C-63 Terminal Effector CD8' CD45RA' (3) 	C-52 Early Like Effector CD4*	
 C-55 Early Effector CD4* (3) C-56 Central Memory CD4* (1) C-57 Central Memory CD4* (2) C-58 Central Memory CD4* (3) C-59 T CD8* Naive (1) C-60 T CD8* Naive (2) C-61 Terminal Effector CD8* CD45RA* (1) C-62 Terminal Effector CD8* CD45RA* (2) C-63 Terminal Effector CD8* CD45RA* (3) 	C-53 Early Effector CD4* (1)	
 C-56 Central Memory CD4* (1) C-57 Central Memory CD4* (2) C-58 Central Memory CD4* (3) C-59 T CD8* Naive (1) C-60 T CD8* Naive (2) C-61 Terminal Effector CD8* CD45RA* (1) C-62 Terminal Effector CD8* CD45RA* (2) C-63 Terminal Effector CD8* CD45RA* (3) 	C-54 Early Effector CD4* (2)	
 C-57 Central Memory CD4* (2) C-58 Central Memory CD4* (3) C-59 T CD8* Naive (1) C-60 T CD8* Naive (2) C-61 Terminal Effector CD8* CD45RA* (1) C-62 Terminal Effector CD8* CD45RA* (2) C-63 Terminal Effector CD8* CD45RA* (3) 		
 C-58 Central Memory CD4* (3) C-59 T CD8' Naive (1) C-60 T CD8' Naive (2) C-61 Terminal Effector CD8' CD45RA* (1) C-62 Terminal Effector CD8' CD45RA* (2) C-63 Terminal Effector CD8' CD45RA* (3) 	C-56 Central Memory CD4 ⁺ (1)	
C-59 T CD8' Naive (1) C-60 T CD8' Naive (2) C-61 Terminal Effector CD8' CD45RA' (1) C-62 Terminal Effector CD8' CD45RA' (2) C-63 Terminal Effector CD8' CD45RA' (3)		
 C-60 T CD8* Naive (2) C-61 Terminal Effector CD8* CD45RA* (1) C-62 Terminal Effector CD8* CD45RA* (2) C-63 Terminal Effector CD8* CD45RA* (3) 		
C-61 Terminal Effector CD8* CD45RA* (1) C-62 Terminal Effector CD8* CD45RA* (2) C-63 Terminal Effector CD8* CD45RA* (3)		
 C-62 Terminal Effector CD8* CD45RA* (2) C-63 Terminal Effector CD8* CD45RA* (3) 		
C-63 Terminal Effector CD8* CD45RA* (3)		
C-64 Terminal Effector CD8* CD45RA* (4)		
C-65 Terminal Effector CD8 [*] (1)		
C-66 Terminal Effector CD8* (2)		
C-67 Early Effector CD8 [*] (1)	C-67 Early Effector CD8* (1)	





主 Control 🔁 EoE





NR-PrePPI 喜 R-PrePPI 蕼 % of total

